HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Purev, E. Articles by Herlyn, D. Search for Related Content PubMed PubMed Citation Articles by Purev, E. Articles by Herlyn, D.

Immune Responses of Breast Cancer Patients to Mutated Epidermal Growth Factor Receptor (EGF-RvIII, EGF-R, and de2–7 EGF-R)¹

Enkhtsetseg Purev^*, Dewei Cai^*, Eric Miller, Rolf Swoboda^*, Ted Mayer, Andres Klein-Szanto, Francesco M. Marincola^¶, Rosemarie Mick^||, Laszlo Otvos^*, William Wunner^*, Brigitte Birebent^*, Rajasekharan Somasundaram^*, Carol J. Wikstrand, Darell Bigner, Angela DeMichele^#, Geza Acs^**, Jesse A. Berlin^|| and Dorothee Herlyn^2,*

^* The Wistar Institute, Philadelphia, PA 19104; Virtua Memorial Hospital, Burlington County, Mt. Holly, NJ 08060; Albert Einstein Medical Center, Philadelphia, PA 19141; Fox Chase Cancer Center, Philadelphia, PA 19111; ^¶ Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892; Departments of ^|| Biostatistics and Epidemiology, ^# Medicine, and ^** Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104; and Duke University, Durham, NC 27710

Mutated epidermal growth factor receptor (EGF-RvIII, EGF-R, and de2–7 EGF-R) is the result of an 801-bp deletion within the extracellular domain of wild-type EGF-R and is expressed by breast carcinomas, but not by normal breast tissues. EGF-RvIII is expressed both on the surface and in the cytoplasm of tumor cells. Thus, EGF-RvIII is a potential tumor-specific target for both Abs and T cells. However, it is not known whether breast cancer patients can raise immune responses to EGF-RvIII expressed by their tumors. The demonstration of EGF-RvIII-specific immune responses in patients would suggest that immunization of patients with EGF-RvIII vaccines is feasible, because these vaccines may boost a pre-existing immune response. We have evaluated humoral and cellular immune responses to EGF-RvIII in 16 breast cancer patients and three healthy donors. Seven of 16 patients developed EGF-RvIII-specific Abs that bound to isolated EGF-RvIII protein or the protein expressed by EGF-RvIII-transfected mouse fibroblasts. The Abs that bound to EGF-RvIII did not bind to wild-type EGF-R, and anti-EGF-RvIII Abs were not found in the sera of healthy donors. Three patients had EGF-RvIII peptide-specific lymphoproliferative responses, and two of these patients also had humoral immune responses. Humoral and cellular immune responses correlated with EGF-RvIII expression by patients’ tumors in most cases. These studies demonstrate that breast cancer patients specifically recognize EGF-RvIII with an overall immune response rate of 50%, suggesting that patients may benefit from vaccination against EGF-RvIII, boosting pre-existing immune responses.

This article has been cited by other articles:

				R. Somasundaram, R. Swoboda, L. Caputo, L. Otvos, B. Weber, P. Volpe, P. van Belle, S. Hotz, D. E. Elder, F. M. Marincola, et al. Human Leukocyte Antigen-A2-Restricted CTL Responses to Mutated BRAF Peptides in Melanoma Patients. Cancer Res., March 15, 2006; 66(6): 3287 - 3293. [Abstract] [Full Text] [PDF]